Clovis up 10% premarket on positive trial data

Phase 1 results for Clovis Oncology's (CLVS) EGFR inhibitor CO-1686 show a 64% objective response rate in non-small cell lung cancer patients with the T790M mutation.

Median duration of response is undetermined, but progression-free survival greater than six months has been observed in evaluable heavily-pretreated patients with the T790M mutation.

The drug was well-tolerated in 61 of 62 patients.

The company expects to submit an NDA for CO-1686 in 2015.

202 mutual funds have positions, up from 127 a year earlier.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs